Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $78.56

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned an average recommendation of “Hold” from the twelve research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $78.5556.

A number of equities research analysts recently weighed in on HALO shares. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $48,754,030. The trade was a 1.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the sale, the chief operating officer directly owned 7,055 shares in the company, valued at approximately $477,200.20. The trade was a 55.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 118,857 shares of company stock worth $8,279,587 in the last three months. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. DLD Asset Management LP grew its stake in shares of Halozyme Therapeutics by 20.0% in the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Halozyme Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after buying an additional 25,731 shares in the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $128,201,000. Finally, William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $124,031,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $67.31 on Wednesday. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. Halozyme Therapeutics has a fifty-two week low of $47.50 and a fifty-two week high of $82.22. The firm has a fifty day moving average price of $68.99 and a two-hundred day moving average price of $68.78. The company has a market cap of $7.97 billion, a PE ratio of 27.03, a price-to-earnings-growth ratio of 0.27 and a beta of 1.03.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.